trending Market Intelligence /marketintelligence/en/news-insights/trending/cEGJ9ZexYvsQVRF0FDRaQQ2 content esgSubNav
In This List

US FDA accepts Eli Lilly's application for nonopioid migraine treatment

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


US FDA accepts Eli Lilly's application for nonopioid migraine treatment

The U.S. Food and Drug Administration accepted Eli Lilly and Co.'s Biologics License Application to review galcanezumab for the prevention of migraine in adults.

The application includes results from three phase 3 studies, where the medicine showed a statistically significant decrease in the average number of monthly migraine headache days compared to placebo.

Galcanezumab is submitted for use as a once-monthly, self-administered injection via auto-injector pen or prefilled syringe.

Galcanezumab represents the first of three investigational, nonopioid treatments being developed as part of Eli Lilly's overall pain portfolio. The portfolio also includes lasmiditan for the acute treatment of migraine and tanezumab, developed in partnership with Pfizer Inc., for the treatment of osteoarthritis, chronic low back pain and cancer pain.